OXC-101 as a new therapy for AML
| Reference number | |
| Coordinator | Oxcia AB |
| Funding from Vinnova | SEK 2 776 067 |
| Project duration | April 2023 - December 2025 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Swelife and Medtech4Health - Collaborative projects for better health autumn 2022 |
Important results from the project
OXC-101, a mitotic MTH1 inhibitor, is under development as a novel treatment for refractory/relapsed (R/R) AML. In this project the goal was to investigate the safety and efficacy of OXC-101 in combination with one of the standard treatments in R/R AML patients, to integrate ex vivo precision medicine screen to identify responders, to develop a business plan and obtain Orphan Drug Designation. The goals have largely been met. The clinical study has been expanded and will continue.
Expected long term effects
The results of this study have laid the foundation for the continued development of OXC-101 in AML. The collaboration between the partners demonstrates how precision medicine can strengthen clinical trials. Obtaining ODD for OXC-101 in AML from both the FDA and EMA strengthens its potential, increases market protection and has generated interest from potential partners and investors. AML is an aggressive blood cancer with a high medical need where OXC-101 has potential as a future new treatment.
Approach and implementation
In this project, Karolinska Institutet, Karolinska University hospital, Örebro University hospital and Oxcia AB have collaborated to develop a new anti-cancer drug for AML patients. The parties´ different expertise has been complementary. Translational project meetings have led to new ideas and strengthened the development of OXC-101. The project was affected by external factors that delayed the start of the clinical study. The clinical study will therefore continue after the end of the grant.